Editas Medicine vs Ocular Therapeutix
Ocular Therapeutix is the larger business, with $52.0m of revenue in fiscal 2025 against $40.5m for Editas Medicine (1.3 times as much). Editas Medicine grew faster (25.4% against -18.5%). Editas Medicine kept more of each dollar of sales as profit: a net margin of -395.0% against -511.9%. Ocular Therapeutix carries less debt relative to equity (10.9% against 214.8%).
| Latest fiscal year | Editas MedicineEDIT, 2025 | Ocular TherapeutixOCUL, 2025 |
|---|---|---|
| Revenue | $40.5m | $52.0m |
| Revenue growth | 25.4% | -18.5% |
| Net income | −$160m | −$266m |
| Operating margin | -394.9% | -519.8% |
| Net margin | -395.0% | -511.9% |
| Return on equity | -198.1% | -54.9% |
| Free cash flow | −$166m | −$217m |
| Cash | $147m | $737m |
| Total debt | $58.6m | $71.3m |
| Debt to equity | 214.8% | 10.9% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 87 | 325 |
| Market value | $252m | $1.48bn |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | 17 (Weak) |
| Insider trades, 12 months | 0 buys, 14 sales | 1 buys, 29 sales |